Please use this identifier to cite or link to this item:
Title: Preliminary consultation on preferred product characteristics of benzathine penicillin G for secondary prophylaxis of rheumatic fever.
Authors: Wyber, Rosemary
Boyd, Ben J
Colquhoun, Samantha
Currie BJ
Engel, Mark
Kado, Joseph
Karthikeyan, Ganesan
Sullivan, Mark
Saxena, Anita
Sheel, Meru
Steer, Andrew
Mucumbitsi, Joseph
Zühlke, Liesl
Carapetis, Jonathan
Citation: Drug delivery and translational research 2016; 6(5): 572-8
Abstract: Rheumatic fever is caused by an abnormal immune reaction to group A streptococcal infection. Secondary prophylaxis with antibiotics is recommended for people after their initial episode of rheumatic fever to prevent recurrent group A streptococcal infections, recurrences of rheumatic fever and progression to rheumatic heart disease. This secondary prophylaxis must be maintained for at least a decade after the last episode of rheumatic fever. Benzathine penicillin G is the first line antibiotic for secondary prophylaxis, delivered intramuscularly every 2 to 4 weeks. However, adherence to recommended secondary prophylaxis regimens is a global challenge. This paper outlines a consultation with global experts in rheumatic heart disease on the characteristics of benzathine penicillin G formulations which could be changed to improve adherence with secondary prophylaxis. Characteristics included dose interval, pain, administration mechanism, cold chain independence and cost. A sample target product profile for reformulated benzathine penicillin G is presented.
Click to open PubMed article:
Journal title: Drug delivery and translational research
Publication Date: 2016
Type: Journal Article
DOI: 10.1007/s13346-016-0313-z
Appears in Collections:(a) NT Health Research Collection

Files in This Item:
There are no files associated with this item.

Items in ePublications are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing